3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Neoplasms
13
Venous Thromboembolism
11
Venous Thrombosis
4
Multiple Myeloma
3
Upper Extremity Deep Vein Thrombosis
2
Thrombosis
2
Pulmonary Embolism
2
Lung Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Thromboembolism
1
Stomach Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Prevention of Venous Thromboembolism
1
Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery
1
Pancreatic Neoplasms
1
Lymphoma
1
Leukemia
1
Inflammation
1
Immune System Diseases
1
Hemorrhage
1
Hematologic Neoplasms
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Dyskinesias
1
Interventions
Docetaxel
277
Prednisone
236
enzalutamide
175
Leuprolide
172
Radiotherapy
164
Abiraterone Acetate
153
Magnetic Resonance Spectroscopy
147
bicalutamide
137
Goserelin
134
Androgen Antagonists
111
Radiosurgery
101
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
100
apalutamide
78
abiraterone
75
gallium 68 PSMA-11
74
Specimen Handling
67
Gonadotropin-Releasing Hormone
58
darolutamide
56
Radiation
56
Triptorelin Pamoate
53
cabazitaxel
49
Zoledronic Acid
49
pembrolizumab
48
Radiotherapy, Intensity-Modulated
47
Flutamide
47
Brachytherapy
47
luprolide acetate gel depot
46
Standard of Care
45
Carboplatin
44
Estramustine
43
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Prostatic Neoplasms
×
Rivaroxaban
×
Clear all
NCT06065592
2023-10-06
CAT_PB
Lebanese University
Phase 1
Unknown
500 enrolled